Moderna (MRNA) Stock Soars 58% After Groundbreaking Melanoma Vaccine Trial Success

TLDR

Table of Contents

Moderna shares skyrocketed approximately 58% during premarket hours Wednesday following positive Phase 3 results for its personalized mRNA melanoma vaccine
The INTerpath-001 study demonstrated that intismeran autogene plus Merck’s Keytruda significantly outperformed Keytruda monotherapy in preventing melanoma from returning
This marks the first successful Phase 3 trial for both a personalized neoantigen therapy and an mRNA cancer treatment
Both companies will present comprehensive data at an upcoming medical conference and discuss regulatory approval pathways with health authorities
Merck (MRK) shares climbed approximately 6% following the announcement; the partnership currently has nine Phase 2 and Phase 3 studies underway targeting various cancer types

Shares of Moderna surged approximately 58% during premarket trading Wednesday following the announcement that its melanoma vaccine combination demonstrated superior efficacy compared to Keytruda monotherapy in a Phase 3 clinical study. This represents a historic milestone as the first mRNA cancer therapy to achieve Phase 3 success.

Moderna, Inc., MRNA

The clinical study, designated INTerpath-001, recruited approximately 1,100 participants with completely surgically removed stage IIB-IV melanoma. Researchers evaluated intismeran autogene, an experimental mRNA-based personalized neoantigen therapy, administered alongside Merck’s leading immunotherapy agent Keytruda.

The treatment combination successfully achieved its primary goal of recurrence-free survival and an important secondary measure of distant metastasis-free survival. Both outcomes demonstrated statistical significance when compared against Keytruda monotherapy.

MODERNA, MERCK MRNA CANCER VACCINE SUCCEEDS IN PHASE 3$MRNA and $MRK say their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial.

The study was stopped at its first interim analysis after positive… pic.twitter.com/Vk7N1jptd6

— Wall St Engine (@wallstengine) August 19, 2026

This trial also represents the first Phase 3 investigation to demonstrate clinically significant benefits over Keytruda monotherapy in the adjuvant treatment setting for surgically resected melanoma patients without prior systemic treatment exposure.

Merck stock rose approximately 6% following the announcement. S&P 500 futures remained relatively unchanged at the time of disclosure.

The experimental vaccine leverages Moderna’s mRNA platform technology, enabling both companies to customize each treatment dose according to dozens of genetic mutations specific to individual patient tumors. This degree of personalization represents a significant differentiation from earlier cancer vaccine development efforts.

Moderna has successfully automated this personalized manufacturing workflow. Industry analysts project this methodology could support annual revenue reaching billions of dollars.

Why This Matters for Moderna

For Moderna, this achievement represents a transformative milestone. The biotechnology company has experienced shareholder pressure to expand its portfolio beyond COVID-19 vaccines. Last June, five-year Phase 2 follow-up results revealed that cancer recurrence or death was reduced by half among participants receiving the vaccine-Keytruda combination treatment.

A positive Phase 3 outcome now establishes the foundation for regulatory submission. Both partners have indicated plans to share comprehensive trial results with regulatory agencies and explore approval pathways.

Merck’s Strategic Interest

For Merck, the implications are substantial. Keytruda, currently the pharmaceutical industry’s top-selling medication generating $32 billion in revenue last year, will face patent expiration challenges in upcoming years. An approved combination therapy would help compensate for anticipated revenue decline.

The safety characteristics of both therapeutics remained aligned with previous clinical investigations. Researchers did not identify any novel safety concerns throughout the trial period.

The investigation will continue monitoring overall survival as an important secondary measure.

Beyond melanoma treatment, the partnership is conducting nine Phase 2 and Phase 3 investigations spanning lung, bladder, kidney, gastric, and pancreatic malignancies.

Both companies intend to share complete trial data at an upcoming international medical conference.

“Today’s results represent a landmark moment for adjuvant melanoma treatment,” said Georgina Long, the Phase 3 study’s lead researcher and an oncology professor at the University of Sydney.

✨ Limited Time Offer